article thumbnail

Are timely access and robust safety mutually exclusive?

pharmaphorum

And how can regulators balance timely access with robust safety? A new cross-sectional study has found that the FDA green lit 95% of the 89 new oncology therapies approved between 2010 and 2019 before the EMA, with the Europeans trailing the Americans by a median of 241 days. Accelerating safe access. appeared first on.

Safety 95
article thumbnail

Boom, Now Bust: Budget Cuts and Layoffs Take Hold in Public Health

MedCity News

Local health department staffing grew by about 19% from 2019 to 2022, according to a report from the National Association of County and City Health Officials that studied 2,512 of the nation’s roughly 3,300 local departments.

Safety 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Another Astellas gene therapy hits a safety hurdle

pharmaphorum

The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. The post Another Astellas gene therapy hits a safety hurdle appeared first on.

Safety 52
article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

While she is stepping down from her current role, Dame June shared that she still hopes to contribute] “to patient safety and public health in other ways” “It has been an enormous privilege to have led the MHRA through a time of change which is unprecedented in UK medical products regulation.

Safety 111
article thumbnail

FDA pushes Daiichi Sankyo’s quizartinib approval date by three months

Pharmaceutical Technology

Nonetheless, the agency did not require further efficacy and safety data in the application. The drug’s safety was generally manageable, and the rates of Grade 3 and higher treatment-emergent adverse events (TEAEs) were similar. The drug was also scrutinised in an FDA advisory committee (AdCom) meeting in May 2019.

article thumbnail

New Parkinson’s drug formulation “nearly doubles” exposure

European Pharmaceutical Review

Therefore “This could improve the overall safety and tolerability of risvodetinib.” “… compared to the capsules currently in use in the 201 clinical trial, the smaller tablets may overcome challenges patients have swallowing oral medication as a result of their disease.

Safety 98
article thumbnail

10 Trends for online health seekers

World of DTC Marketing

Hand flip wood cube change year 2019 to 2020. 10en : The most consumed pages on most pharma websites is safety information and pages that offer co-pay cards as people try to save money on Rx’s. In my opinion, this is due to pharma being sold on programmatic and the lack of investment in creative. 2020 trend concept.

Media 287